Stockreport

QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)

Qiagen N.V. Common Shares  (QGEN) 
Last qiagen n.v. common shares earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corporate.qiagen.com/investor-relations
PDF KRAS mutations in NSCLC reflect a large underserved patient population with an unmet need for innovative treatment options QIAGEN is developing a tissue-based companion [Read more]